Immunex Enbrel Psoriatic Arthritis 12-Month Data To Follow sBLA Approval
Executive Summary
Immunex plans to submit 12-month, open-label Enbrel data in psoriatic arthritis patients following FDA's Jan. 16 approval of etanercept for the supplemental indication
You may also be interested in...
Amgen/Wyeth Enbrel
Wyeth/Amgen's Enbrel clears FDA Aug. 21 for supplemental indication of "inhibiting the progression of structural damage of active arthritis in patients with psoriatic arthritis." Enbrel (etanercept) was approved for "reducing the signs and symptoms" of psoriatic arthritis in 2002 (1"The Pink Sheet" Jan. 21, 2002, p. 25)...
Amgen/Wyeth Enbrel
Wyeth/Amgen's Enbrel clears FDA Aug. 21 for supplemental indication of "inhibiting the progression of structural damage of active arthritis in patients with psoriatic arthritis." Enbrel (etanercept) was approved for "reducing the signs and symptoms" of psoriatic arthritis in 2002 (1"The Pink Sheet" Jan. 21, 2002, p. 25)...
Enbrel Shortage Strategies: Clinical Trials Will Provide “Bolus” Of Patients
Immunex' ongoing Enbrel clinical trials will help provide a "bolus" of patients for the rheumatoid arthritis agent once the company expands its commercial capacity for the biologic